Department of Thyroid and Breast Surgery, Shanghai First People's Hospital Baoshan Branch, No. 101, North Tongtai Road, Shanghai, 200940, China.
Department of Pharmacy, Shanghai First People's Hospital Baoshan Branch, Shanghai, 200940, China.
Clin Exp Med. 2020 Aug;20(3):417-425. doi: 10.1007/s10238-020-00625-4. Epub 2020 Apr 11.
Previous researches have indicated that miR-4317 was aberrantly expressed in several tumors. However, the potential role of miR-4317 in breast cancer is still unclear. The aim of this study was to investigate the potential role of miR-4317 in breast cancer. The relative expression levels of miR-4317 were detected in breast cancer tissues and cell lines using qRT-PCR analysis. The Kaplan-Meier survival curve and multivariate Cox regression analyses were used to investigate the prognostic significance of miR-4317 in breast cancer. CCK-8 and Transwell assays were performed to evaluate the effects of miR-4317 on cell proliferation, migration, and invasion. The results showed that miR-4317 expression was decreased in breast cancer tissues and cell lines. Downregulation of miR-4317 was significantly associated with lymph node metastasis, TNM stage, and poor prognosis. Overexpression of miR-4317 inhibited proliferation, migration, and invasion of breast cancer cells, while downregulation of miR-4317 exhibited the opposite effects. MYD88 may be a direct target of miR-4317. The results suggest miR-4317 may play a tumor suppressor role in breast cancer and inhibit proliferation, migration, and invasion of breast cancer cells by targeting MYD88. The findings provide novel evidence of miR-4317 as a potential prognostic biomarker and therapeutic target for breast cancer.
先前的研究表明,miR-4317 在几种肿瘤中表达异常。然而,miR-4317 在乳腺癌中的潜在作用尚不清楚。本研究旨在探讨 miR-4317 在乳腺癌中的潜在作用。使用 qRT-PCR 分析检测乳腺癌组织和细胞系中 miR-4317 的相对表达水平。Kaplan-Meier 生存曲线和多变量 Cox 回归分析用于研究 miR-4317 在乳腺癌中的预后意义。CCK-8 和 Transwell 测定用于评估 miR-4317 对细胞增殖、迁移和侵袭的影响。结果表明,miR-4317 在乳腺癌组织和细胞系中表达降低。miR-4317 的下调与淋巴结转移、TNM 分期和不良预后显著相关。miR-4317 的过表达抑制乳腺癌细胞的增殖、迁移和侵袭,而 miR-4317 的下调则表现出相反的效果。MYD88 可能是 miR-4317 的直接靶标。研究结果表明,miR-4317 在乳腺癌中可能发挥肿瘤抑制作用,通过靶向 MYD88 抑制乳腺癌细胞的增殖、迁移和侵袭。这些发现为 miR-4317 作为乳腺癌潜在的预后生物标志物和治疗靶点提供了新的证据。